Anti-transferrin receptor (TFR) antibodies and their use
Novel anti-TfR antibodies with high specificity and affinity address the need for targeted delivery of molecular payloads to TfR-expressing cells, enhancing therapeutic efficacy in neurological and muscular diseases.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- DYNE THERAPEUTICS INC
- Filing Date
- 2026-01-15
- Publication Date
- 2026-05-26
AI Technical Summary
Existing technologies lack effective and specific antibodies that can bind to transferrin receptors (TfRs) with high affinity and specificity, particularly for diagnostic and therapeutic applications, especially in delivering molecular payloads to target cells or tissues.
Development of novel anti-TfR antibodies with high specificity and affinity, conjugated to molecular payloads, allowing targeted delivery to cells or tissues expressing TfR, including those in the brain and muscle, and demonstrating superior activity compared to existing antibodies.
The anti-TfR antibodies enable efficient delivery of molecular payloads to target cells, such as muscle and brain cells, overcoming the challenge of delivering across the blood-brain barrier, and are effective in treating neurological and muscular diseases.
Smart Images
Figure 2026086434000001_ABST